To establish a production facility for sex hormone and contraceptive tablets, a large investment is required, so a feasibility study is needed. The feasibility study covers technical, managerial, legal, market, technical, financial, economic aspects. The study will rely on sales targets for several years and the expenses of investment. The study depended on projected sales targets spanning several years and the related investment costs. Starting from the market share of sex hormone and contraceptive tablets in Indonesia in 2023, the analysis was conducted holistically with regard to the evolution of a product sales portfolio. Based on IQVIA data from 2023, the market potential for sex hormone and contraceptive tablets in Indonesia was IDR 774,870,335,382, with a MAT GR of 18% and a 3-year CAGR from 2021 to 2023 of 9%. With an IRR of 53% and a PBP of 2.13 years, the NPV obtained following an analysis of 12 portfolio products to be developed was IDR 191,886,357,660. It was thus decided that the investment was doable. Following the investment feasibility test, a sensitivity study was done to observe NPV value changes against revenue and Cost of Goods Sold. The results of the sensitivity test showed that the investment was still feasible to run at a change in the increase in Cost of Goods Sold of 30%, and a decrease in revenue value of 15%.